Furthermore, we found that MYBL1 was overexpression in several gastrointestinal cancers (Supplementary Fig. S5) and the clinical relevance of MYBL1 and ANGPT2 was further confirmed in multiple cancers of published profiles: pancreatic cancer (NCBI/GEO/GSE 17891; r = 0.87; p = 0.003; n = 47); esophageal carcinoma (NCBI/GEO/GSE 32701; r = 0.43; p < 0.001; n = 40); stomach adenocarcinoma (TCGA; r = 0.42; P < 0.01; n = 405); colon cancer (NCBI/GEO/GSE 4183; r = 0.52; p = 0.007; n = 52) (Fig. 7C). This evidence concerns the gene MYBL1 and gastric adenocarcinoma.